Allogene Therapeutics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Allogene Therapeutics stock has a consensus rating of "Buy" and an average price target of $8.49. The average 1-year stock price forecast is 324.50% higher than the current stock price, while the lowest is $3.85 (+92.50%) and the highest is $14 (+600.00%).

Price Target: $8.49 (+324.50%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$3.85	$8.49	$9.00	$14
Change	+92.50%	+324.50%	+350.00%	+600.00%

Analyst Ratings

The average analyst rating for Allogene Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	10	10	10	10	9	8
Buy	3	3	3	3	3	3
Hold	1	1	1	2	2	2
Sell	1	1	1	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	15	15	14	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Biren Amin Piper Sandler	Piper Sandler	Buy Maintains $10	Buy	Maintains	$10	+400.00%	May 29, 2026
Sami Corwin William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 14, 2026
Matthew Biegler Oppenheimer	Oppenheimer	Buy Reiterates $7	Buy	Reiterates	$7	+250.00%	May 14, 2026
Luca Issi RBC Capital	RBC Capital	Buy Maintains $9	Buy	Maintains	$9	+350.00%	May 14, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Buy Maintains $14	Buy	Maintains	$14	+600.00%	May 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

6.00K

Revenue Next Year

12.97M

from 6.00K

216,118.50%

from 6.00K

EPS This Year

-0.61

from -0.85

EPS Next Year

-0.68

from -0.61

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	114.09M	156.00K	95.00K	22.00K	-	6.00K
Gross Profit	-106.09M	-256.23M	-242.82M	-192.28M	-150.15M	5.28K
Gross Margin	-92.99%	-164,250.64%	-255,598.95%	-873,986.36%	-	88.00%
Operating Income	-180.19M	-335.54M	-314.49M	-257.48M	-206.93M	-213.96M
Net Income	-182.05M	-340.41M	-327.27M	-257.59M	-190.89M	-196.57M
EPS	-	-	-	-	-0.85	-0.61
Free Cash Flow	-85.97M	-111.74M	-134.26M	-99.13M	-80.73M	-152.00M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	60,000
Avg	6,000
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	1,058,233.3%
Avg	216,118.5%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-0.58
Avg	-0.61
Low	-0.66

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-